Penn Pharma Invests in Manufacturing Capacity

Article

Penn Pharma has announced plans to invest in additional tablet manufacturing and coating capacity.

Penn Pharma has announced its plans to invest in additional tablet manufacturing and coating capacity to meet customer demand.  This investment is in addition to the £14 million ($21.2 million) recently invested in a solid dose contained manufacturing facility to handle potent active pharmaceutical ingredients.  
  
The new £3 million ($4.5 million) investment follows the recent completion of Penn Pharma’s new 15,000-ft2 site for the clinical and commercial manufacture of tablets and capsules.

Penn Pharma has been providing pharmaceutical services for more than 30 years and employs 275 staff on its two sites in South Wales, UK.

 

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Behind the Headlines, Episode 10
Related Content